{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:31:27Z","timestamp":1787941887891,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Improvements in blood culture techniques and molecular-based diagnostics have led to increased recognition of <jats:italic toggle=\"yes\">Kingella kingae<\/jats:italic> as an invasive human pathogen causing bacteremia, septic arthritis, osteomyelitis and endocarditis in young children. Serious disease and potentially life-threatening complications of infection due to <jats:italic toggle=\"yes\">K. kingae<\/jats:italic> necessitate timely identification and appropriate antimicrobial therapy. Ceftaroline is a fifth-generation broad spectrum cephalosporin that possesses activity against Gram-negative and Gram-positive pathogens similar to third-generation cephalosporins, but also includes methicillin-resistant <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>. This study reports the <jats:italic toggle=\"yes\">in vitro<\/jats:italic> activity of ceftaroline and comparator agents against an international collection of <jats:italic toggle=\"yes\">K. kingae<\/jats:italic> isolates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A collection of 308 <jats:italic toggle=\"yes\">K. kingae<\/jats:italic> isolates was obtained primarily from children with bacteremia, endocarditis, osteoarticular infections or from asymptomatic pediatric carriers. Isolates were tested for antibiotic susceptibility using Clinical and Laboratory Standard Institute broth microdilution methodology and screened for \u03b2-lactamase production using a nitrocefin chromogenic test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Ceftaroline inhibited all <jats:italic toggle=\"yes\">K. kingae<\/jats:italic> isolates at \u22640.06\u2009mg\/L (MIC<jats:sub>50\/90<\/jats:sub>, 0.015\/0.03\u2009mg\/L). Ceftaroline MICs were similar to results with ceftriaxone (MIC<jats:sub>50\/90<\/jats:sub>, 0.015\/0.015\u2009mg\/L), meropenem (MIC<jats:sub>50\/90<\/jats:sub>, 0.015\/0.015\u2009mg\/L) and ampicillin\u2013sulbactam (MIC<jats:sub>50\/90<\/jats:sub>, 0.06\/0.06\u2009mg\/L). Ceftaroline MICs were slightly lower than MICs for cefuroxime and amoxicillin\/clavulanate (MIC<jats:sub>50\/90<\/jats:sub>, 0.06\/0.12\u2009mg\/L). MICs were high for clindamycin (MIC<jats:sub>50\/90<\/jats:sub>, 2\/4\u2009mg\/L) and oxacillin (MIC<jats:sub>50\/90<\/jats:sub>, 4\/8\u2009mg\/L). Sixteen isolates (5.2%) yielded a positive nitrocefin test indicating production of \u03b2-lactamase; ceftaroline demonstrated equivalent MICs against \u03b2-lactamase<jats:bold>\u2013<\/jats:bold>positive and \u03b2-lactamase<jats:bold>\u2013<\/jats:bold>negative strains (MIC<jats:sub>50\/90<\/jats:sub>, 0.015\/0.3\u2009mg\/L).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The potent activity of ceftaroline against this large international collection of <jats:italic toggle=\"yes\">K. kingae<\/jats:italic> isolates supports further clinical evaluation in children.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003799","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T21:13:49Z","timestamp":1675372429000},"page":"206-211","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["In vitro Activity of Ceftaroline Against an International Collection of Kingella kingae Isolates Recovered From Carriers and Invasive Infections"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-6855","authenticated-orcid":false,"given":"Joshua M.","family":"Maher","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-1137","authenticated-orcid":false,"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1189-1895","authenticated-orcid":false,"given":"Holly K.","family":"Huynh","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Porsch","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-9510","authenticated-orcid":false,"given":"Joseph W.","family":"St. Geme III","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Yagupsky","sequence":"additional","affiliation":[{"name":"Soroka University Medical Center, Be\u2019er-Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bradley","sequence":"additional","affiliation":[{"name":"University of California San Diego School of Medicine, San Diego, CA"},{"name":"Rady Children\u2019s Hospital, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1128\/CMR.00028-14","article-title":"Kingella kingae: carriage, transmission, and disease.","volume":"28","author":"Yagupsky","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"e00060","DOI":"10.1128\/mSphere.00060-17","article-title":"The type a and type b polysaccharide capsules predominate in an international collection of invasive Kingella kingae isolates.","volume":"2","author":"Porsch","year":"2017","journal-title":"mSphere"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cmi.2017.07.019","article-title":"Antimicrobial susceptibility testing of Kingella kingae with broth microdilution and disk diffusion using EUCAST recommended medium.","volume":"24","author":"Matuschek","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.inf.0000259954.88139.f4","article-title":"Specific real-time polymerase chain reaction places Kingella kingae as the most common cause of osteoarticular infections in young children.","volume":"25","author":"Chometon","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1542\/peds.2010-1867","article-title":"Kingella kingae: an emerging pathogen in young children.","volume":"127","author":"Yagupsky","year":"2011","journal-title":"Pediatrics"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/INF.0000000000000303","article-title":"High rates of complications following kingella kingae infective endocarditis in children.","volume":"33","author":"Foster","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jpids\/piy063","article-title":"Kingella kingae septic arthritis in an older-than-expected child.","volume":"8","author":"Shahrestani","year":"2018","journal-title":"J Pediatr Infect Dis Soc"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/INF.0b013e31816fc34c","article-title":"Empiric antibiotic therapy for acute osteoarticular infections with suspected methicillin-resistant Staphylococcus aureus or Kingella.","volume":"27","author":"Saphyakhajon","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1128\/AAC.00318-13","article-title":"Characterization of TEM-1 \u03b2-Lactamase-Producing Kingella kingae clinical isolates.","volume":"57","author":"Banerjee","year":"2013","journal-title":"Antimicro Agents Chemother"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1128\/AAC.03562-14","article-title":"First identification of a chromosomally located penicillinase gene in Kingella kingae species isolated in continental Europe.","volume":"58","author":"Basmaci","year":"2014","journal-title":"Antimicro Agents Chemother"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijantimicag.2019.08.012","article-title":"Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.","volume":"54","author":"Welte","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13756-020-00829-z","article-title":"Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016).","volume":"9","author":"Zhang","year":"2020","journal-title":"Antimicro Resist Infect Control"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/20009666.2017.1374107","article-title":"Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital.","volume":"7","author":"Karki","year":"2017","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.00330-12","article-title":"Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program.","volume":"56","author":"Flamm","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"R16-20250614","first-page":"iii11","article-title":"Ceftaroline fosamil: a new broad-spectrum cephalosporin.","volume":"66","author":"Laudano","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkp503","article-title":"Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae.","volume":"65","author":"Moisan","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1128\/JCM.01287-15","article-title":"Development of a pefloxacin disk diffusion method for detection of fluoroquinolone-resistant Salmonella enterica.","volume":"53","author":"Skov","year":"2015","journal-title":"J Clin Microbiol"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jpeds.2017.11.025","article-title":"The contemporary bacteriologic epidemiology of osteoarticular infections in children in Switzerland.","volume":"194","author":"Juchler","year":"2018","journal-title":"J Pediatr"},{"key":"R22-20250614","first-page":"313","article-title":"Etiology and medical management of acute suppurative bone and joint infections in pediatric patients.","volume":"2","author":"Jackson","year":"1983","journal-title":"J Pediatr Orthop"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00006565-199902000-00012","article-title":"Etiology of septic arthritis in children: an update for the 1990s.","volume":"15","author":"Luhmann","year":"1999","journal-title":"Pediatr Emerg Care"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/MOP.0b013e32835c2b42","article-title":"Osteomyelitis and septic arthritis in children: current concepts.","volume":"25","author":"Dodwell","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00006454-198611000-00014","article-title":"Pyogenic arthritis in infants and children: a review of 95 cases.","volume":"5","author":"Welkon","year":"1986","journal-title":"Pediatr Infect Dis J"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/01241398-199911000-00003","article-title":"Reduction in osteomyelitis and septic arthritis related to Haemophilus influenzae type B vaccination.","volume":"19","author":"Howard","year":"1999","journal-title":"J Pediatr Orthop"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/INF.0000000000001697","article-title":"Osteoarticular infections caused by Streptococcus pneumoniae in children in the post-pneumococcal conjugate vaccine era.","volume":"36","author":"Olarte","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10096-012-1807-3","article-title":"Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review.","volume":"32","author":"Vardakas","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/BPO.0000000000001744","article-title":"Primary septic arthritis among children 6 to 48 months of age: Implications for PCR acquisition and empiric antimicrobial selection.","volume":"41","author":"Villani","year":"2021","journal-title":"J Pediatr Orthop"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/INF.0000000000003357","article-title":"Kingella kingae spondylodiscitis: treatment failure with flucloxacillin.","volume":"41","author":"Kenne","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.pcl.2012.12.006","article-title":"Bone and joint infections.","volume":"60","author":"P\u00e4\u00e4kk\u00f6nen","year":"2013","journal-title":"Pediatr Clin North Am"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:03:49Z","timestamp":1749945829000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003799","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,28]]}}}